ArticleBritish journal of clinical pharmacology2012
Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects.
Article in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.International journal of chronic obstructive pulmonary disease · 2018Trial
- Inflammation induced by inhaled lipopolysaccharide depends on particle size in healthy volunteers.British journal of clinical pharmacology · 2016Trial
- Dissociation between systemic and pulmonary anti-inflammatory effects of dexamethasone in humans.British journal of clinical pharmacology · 2016Trial
- Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human.BMC pharmacology & toxicology · 2014Trial
- Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development.BMC pulmonary medicine · 2013Trial
- An inhibitor of RORγ for chronic pulmonary obstructive disease treatment.Scientific reports · 2022Article
- Article
- Association of exacerbation phenotype with the sputum microbiome in chronic obstructive pulmonary disease patients during the clinically stable state.Journal of translational medicine · 2021Article
- The Effect of Modified Porcine Surfactant Alone or in Combination with Polymyxin B on Lung Homeostasis in LPS-Challenged and Mechanically Ventilated Adult Rats.Molecules (Basel, Switzerland) · 2020Article
- Like Cures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome.Frontiers in pharmacology · 2020Review
- Use of autologousThorax · 2019Article
- Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease.British journal of clinical pharmacology · 2015Article
- Indoor and outdoor exposure to ultrafine, fine and microbiologically derived particulate matter related to cardiovascular and respiratory effects in a panel of elderly urban citizens.International journal of environmental research and public health · 2015Article
- Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.Respiratory research · 2014Review
- Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA.PloS one · 2014Article
- Lipopolysaccharide induces endoplasmic store Ca2+-dependent inflammatory responses in lung microvessels.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLipopolysaccharide (LPS) is a TLR4 agonist which activates NFκB dependent cytokine production. We investigated LPS inhalation in healthy smokers as a model of COPD bacterial exacerbations. We studied safety, reproducibility, the translocation of the NFκB subunit p65 in sputum cells and changes in systemic biomarkers of inflammation.
methodsTwelve smokers inhaled 5 and 30 µg LPS and safety was monitored over 24 h. IL-6, CRP, CCl-18, SP-D, CC-16 and β-defensin 2 were measured in serum samples collected at baseline, 4, 8 and 24 h. Sputum was induced at baseline, 6 and 24 h for cell counts and p65 expression. Repeated challenges were performed after a 2 week interval in 10 smokers.
resultsLPS inhalation was well tolerated. Significant increases occurred in sputum neutrophil counts with both doses, with a maximum increase of 21.5% at 6 h after 30 µg which was reproducible, r(i ) (intraclass correlation coefficient) = 0.88. LPS increased sputum cell nuclear p65 translocation and phospho-p65 expression. All of the serum biomarkers increased following challenge but with different temporal patterns. DISCUSSION: Inhaled LPS challenge in smokers causes pulmonary and systemic inflammation that involves NFκB activation. This appears to be a suitable model for studying bacterial exacerbations of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.